Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

@article{OBrien2003ImatinibCW,
  title={Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.},
  author={S. O’Brien and F. Guilhot and R. Larson and I. Gathmann and M. Baccarani and F. Cervantes and J. Cornelissen and T. Fischer and A. Hochhaus and T. Hughes and K. Lechner and J. Nielsen and P. Rousselot and J. Reiffers and G. Saglio and J. Shepherd and B. Simonsson and A. Gratwohl and J. Goldman and H. Kantarjian and K. Taylor and G. Verhoef and A. Bolton and R. Capdeville and B. Druker},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 11},
  pages={
          994-1004
        }
}
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover… Expand
3,244 Citations

Paper Mentions

Observational Clinical Trial
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular… Expand
ConditionsLeukemia, Myelogenous, Chronic, BCR-ABL Positive
InterventionDrug
Observational Clinical Trial
To expresse TIGIT in NK Cells in Patients with Chronic Myeloid Leukemia  
ConditionsChronic Myeloid Leukemia
InterventionDiagnostic Test
Interventional Clinical Trial
The Personalized Discovery Process is the only program offering patients treatment recommendations based on an empirically constructed Drosophila "fly" model of their disease… Expand
ConditionsColon Cancer, Medullary Thyroid Cancer
InterventionOther
Interventional Clinical Trial
The current standard therapy in previously untreated adults with chronic phase (CP) of CML is imatinib and the result of long-term follow-up of IRIS study proves that imatinib for CML… Expand
ConditionsChronic Myeloid Leukemia in Myeloid Blast Crisis, Untreated Adult Acute Myeloid Leukemia
InterventionDrug
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
  • 1,241
  • PDF
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
  • 3,114
  • PDF
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
  • 1,216
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
  • 1,994
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
  • 4,774
  • PDF
...
1
2
3
4
...